Andrew joined GCMI+T3 Labs in 2009. He has led the site transfer and operational start-up of T3 Labs in a new $20 million world-class facility, re-focused the organization on quality-first service model, built sustainable relationships with Fortune 500 medical device manufacturers, academic and healthcare institutions, and startups alike, established a team of highly-qualified independent consultant-Program Leaders that serve over 150 customers annually, and expanded GCMI and T3 Labs’ service offerings to 13 therapeutic and service-oriented programs.
In addition to leading deal-flow and account management for GCMI+T3 Labs services, GCMI recently launched a MedTech Accelerator for which he is accountable. He is also involved in local and state economic development initiatives for life sciences and healthcare.Prior to moving to GCMI and T3 Labs, he led corporate development raising over $330 million, built and directed three project management offices, support dozens of global development and product launch programs, provided independent consulting services, and conducted laboratory research for several companies. These companies include Abbott Laboratories/Solvay Pharmaceuticals, Bristol-Myers Squibb/DuPont/Merck, an GA Tech ATDC start-up, and the University of Pennsylvania. He holds an M.B.A in International Business from the Alfred Lerner College of Business and Economics, University of Delaware and a B.S. in Chemistry from Davidson College.
CEO GCMI/T3 Labs
Tiffany has spent more than 15 years bringing innovative medical technology from benchtop to bedside. She joined GCMI in 2011 to lead its startup phase, establishing overall strategic vision, building strategic relationships and bringing together key stakeholders of the medical device ecosystem. Her strong background in medical devices, commitment to fostering innovation and understanding of business strategies have propelled her into a leadership role in the Southeast and brought her into the national spotlight. Tiffany earned a BBA in International Business from Loyola University and an MBA from Georgetown University McDonough School of Business.
Wilson joined GCMI from Scientific Intake, where she served as the Vice President of Business Development and Strategy, evaluating marketing and distribution opportunities and driving product development projects for the global obesity market. Prior to Scientific Intake, she was Vice President of Corporate Strategy and Finance at ACell, Inc., a regenerative medicine and tissue engineering company based in Columbia, Maryland. At ACell, she led a broad range of initiatives including corporate finance, investor relations, strategic and operational planning, business development, regulatory, and reimbursement.
Tiffany serves as Past-President of the Board of the Southeast Medical Device Association (SEMDA), Founding Member of Medtech Women @ SEMDA, Chair of the T3 Labs Advisory Board, and the Georgia Bio Board of Directors. She is a Member of the National Advisory Council on Innovation and Entrepreneurship (NACIE) at the U.S. Department of Commerce. She led the Sponsorship Committee of the 2013 SEMDA Conference and has served as the Co-Chair of the Medical Device Subcommittee of the Metro Atlanta Chamber Bioscience Leadership Council. In 2015 Tiffany received the prestigious Georgia Bio Community Award and in 2017 was presented with the Industry Growth Award, the highest honor bestowed each year by Georgia Bio. She was recently recognized by Inc. Magazine as one of “17 Inspiring Women to Watch in 2017” and one of Becker Hospital Review’s “110 Women in Medtech to Know in 2017”.
Martin Entwistle, MBA, MB ChB, FRCSEd.
Martin, trained as a physician, has over 25 years senior executive experience in decision-making positions in healthcare, 22 years as a chief executive and entrepreneur, 10 years in health systems innovation. 7 years in pharma and pharma information publishing. Has extensive commercial and entrepreneurial experience including early-stage ventures. His expertise is in the design, development and deployment of data-focussed digital health solutions that drive clinical care outcomes through healthcare transformation and patient engagement. He has led 3 digital health startups and directed a healthcare innovation
center for an $8B not-for-profit California integrated delivery system that used crowd-sourced human-centered design to build data-driven solutions for personalized care and aging-in-place. Responsible for developing the teams that created novel models of care, implemented the supporting business processes to deploy and integrate these with existing clinical information systems. Recognized subject matter expert on care-management systems and digital health. Has published papers and is a regular presenter on these topics at national-level conferences. Current board member and past chair of HL7 New Zealand. Subject matter expert to the Office of the National Coordinator for Health IT on use of patient-generated health data in clinical care.
Aron Starosta, PhD.
Aron is a highly experienced, motivated entrepreneur, and internationally recognized expert on moving early-stage health companies from product development into product sales by building the necessary environments, skills, plans, resourcing and financing. He is an undisputed expert in the establishment and management of health technology accelerators with 20+ programs built, designed, managed or run internationally to date. Aron has 25 years’ experience in technology due diligence specializing in the health and biotechnology sectors, with a proven record of identifying the attributes of success at the earliest stages of company development. Aron also has extensive experience building innovation hubs in billion dollar corporations, governmental and not-for-profit environments. He has also been a pharmaceutical thought leader for medications to treat addiction and is an expert in effecting behavioral change in both patients and start-ups.